Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ekaterina S. Nesterova"'
Autor:
Ekaterina S. Nesterova, Aleksandra F. Saydullaeva, Dmitry G. Sherstnev, Tatiana V. Shelekhova, Tatiana Yu. Klitochenko, Gulnara N. Khusainova, Irina B. Lysenko, Irina S. Lyalina, Marina V. Demchenkova, Svetlana A. Orlova, Andrei V. Proydakov, Мadina V. Betrozova, Natalia V. Fadeeva, Alina A. Gofman, Yana M. Marchenko, Sergey V. Voloshin, Elena A. Pashneva, Vladislav O. Sarzhevskiy, Alina R. Babicheva, Irina B. Bondareva, Natalia N. Glonina, Damir G. Ishchanov, Irina V. Poddubnaya
Publikováno v:
Современная онкология, Vol 25, Iss 4, Pp 422-431 (2023)
Aim. To evaluate the effectiveness and safety of Extimia® BIOCAD (international non-proprietary name: empegfilgrastim) to reduce the incidence and duration of neutropenia, the incidence of febrile neutropenia (FN) and infections associated with FN i
Externí odkaz:
https://doaj.org/article/a4488d8f4b30472c91384c6204fc8dbe
Autor:
Ekaterina S. Nesterova, Aleksandra F. Saydullaeva, Dmitry G. Sherstnev, Tatiana V. Shelekhova, Tatiana Y. Klitochenko, Gulnara N. Khusainova, Irina B. Lysenko, Irina S. Lyalina, Marina V. Demchenkova, Svetlana A. Orlova, Andrei V. Proydakov, Madina V. Betrozova, Natalia V. Fadeeva, Alina A. Gofman, Yana M. Marchenko, Sergey V. Voloshin, Elena A. Pashneva, Vladislav O. Sarzhevskiy, Damir G. Ishchanov, Irina V. Poddubnaya
Publikováno v:
Современная онкология, Vol 24, Iss 1, Pp 80-88 (2022)
Aim. To assess effectiveness and safety of Extimia BIOCAD (INN: empegfilgrastim) used to decrease the rate and duration of neutropenia, the rate of febrile neutropenia and infections that manifest in febrile neutropenia in patients with lymphoprolife
Externí odkaz:
https://doaj.org/article/edd60a9c0c3c4993938d54096b58d543
Autor:
Vladimir I. Vorobyev, Eduard G. Gemdzhian, Liudmila V. Fedorova, Natalia B. Mikhailova, Ridvan K. Ilyasov, Liliia P. Kaleikina, Olga S. Trubyakova, Kamil D. Kaplanov, Elena V. Melnichenko, Elena V. Martynova, Elena P. Yakovleva, Olga Yu. Li, Elena V. Tarasenko, Elena P. Chumakova, Natalia B. Bulieva, Ekaterina S. Nesterova, Oleg V. Margolin, Vera A. Zherebtsova, Lev S. Butaev, Vadim V. Ptushkin
Publikováno v:
Терапевтический архив, Vol 93, Iss 7, Pp 770-777 (2021)
Background. Mantle cell lymphoma (MCL) is a rare and clinically aggressive lymphoma subtype. Current approaches have greatly improved patients outcomes, but relapse is inevitable. In phase IIIII clinical trials, ibrutinib has shown significant activi
Externí odkaz:
https://doaj.org/article/b83a79daf0fc4b7db69564adb35219aa
Autor:
Ekaterina S. Nesterova, Tatyana Yu. Klitochenko, Natalya N. Glonina, Natalya V. Fadeeva, Tatyana A. Sannikova, Irina S. Lyalina, Tatyana V. Shelekhova, Dmitrij G. Sherstnev, Sergey V. Voloshin, Vladislav O. Sarzhevskii, Alina A. Hofman, Damir G. Ichshanov, Irina V. Poddubnaya
Publikováno v:
Современная онкология, Vol 22, Iss 4, Pp 77-84 (2021)
Aim. To assess the efficacy and safety of using the drug Extimia BIOCAD (international nonproprietary name INN: empegfilgrastim) in order to reduce the frequency and duration of neutropenia, the frequency of febrile neutropenia (FN) and infections ma
Externí odkaz:
https://doaj.org/article/f8ac47889d5d41f7a8c9e2650cc5399d
Autor:
Tatyana V. Shelekhova, Natalya N. Glonina, Tatyana Yu. Klitochenko, Irina V. Poddubnaya, Alina A. Hofman, Damir G. Ichshanov, Tatyana A. Sannikova, Ekaterina S. Nesterova, Sergey V. Voloshin, Vladislav O. Sarzhevskii, Natalya V. Fadeeva, Irina S. Lyalina, Dmitrij G. Sherstnev
Publikováno v:
Современная онкология, Vol 22, Iss 4, Pp 77-84 (2021)
Aim. To assess the efficacy and safety of using the drug Extimia BIOCAD (international nonproprietary name INN: empegfilgrastim) in order to reduce the frequency and duration of neutropenia, the frequency of febrile neutropenia (FN) and infections ma
Autor:
Ekaterina S. Nesterova, Sergey K. Kravchenko, Eduard G. Gemdjian, Valeri G. Savchenko, Alla M. Kovrigina
Publikováno v:
Blood. 122:5052-5052
Background Follicular lymphoma (FL) is characterized by clinical heterogeneity. There is a need for easily quantifiable prognostic biomarkers. No consensus has been achieved regarding the prognostic significance of the microvessel density, number of